1700021P04Rik Activators
GluR1 Activators are a set of chemical compounds that serve to augment the activity of the GluR1 protein, a subunit of AMPA-type glutamate receptors involved in fast excitatory synaptic transmission in the central nervous system. Compounds such as Cyclothiazide and Aniracetam are known as positive allosteric modulators of AMPA receptors, and their function is to increase GluR1 activity by preventing desensitization and enhancing the receptor's response to glutamate, respectively. Similarly, ampakines like CX-516, PEPA, IDRA-21, LY404187, and Sunifiram enhance the GluR1-mediated synaptic transmission by increasing the channel opening frequency or the efficiency of glutamate-induced responses, thus facilitating a more robust excitatory signal across the synapse. The chemical compounds classified as 1700021P04Rik Activators are distinguished by their ability to upregulate the expression of the gene 1700021P04Rik in the mouse genome.
The search for these activators often begins with a high-throughput screening process, which is designed to evaluate a vast array of compounds quickly to find those that can elevate the activity of the 1700021P04Rik gene. A typical method employed in this phase is the use of a luciferase reporter assay. In this assay, the promoter region of 1700021P04Rik is attached to the luciferase reporter gene, and activation of this promoter by a compound leads to an increase in luciferase activity, which can be easily measured as a luminescent signal. Chemicals that result in a significant increase in luminescence are marked as potential 1700021P04Rik Activators and subsequently undergo more detailed analysis. Once potential activators are identified, confirmatory tests are conducted to validate their effects.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Isobutylmethylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases, enzymes that break down cAMP and cGMP. By preventing cAMP degradation, IBMX can increase cAMP levels in cells, which may indirectly enhance the activity of 1700021P04Rik by similar mechanisms as forskolin if 1700021P04Rik is part of the cAMP pathway. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. Calcium signaling is a ubiquitous mechanism that can modulate many cellular processes. If 1700021P04Rik is regulated by calcium-dependent kinases or phosphatases, ionomycin could enhance its activity by increasing calcium influx. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). If 1700021P04Rik is a substrate for PKC or is involved in the PKC signaling pathway, PMA could enhance the activity of 1700021P04Rik by activating PKC, which could then directly phosphorylate and activate 1700021P04Rik. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is another calcium ionophore similar to ionomycin. By increasing intracellular calcium, A23187 could potentiate the activation of 1700021P04Rik if it is responsive to calcium signaling, either directly or through calcium-dependent proteins. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. Inhibition of PI3K can lead to a reduction in PIP3 levels, affecting downstream signaling, including AKT. If 1700021P04Rik is negatively regulated by PI3K/AKT signaling, then inhibition by LY294002 could relieve this inhibition and enhance the activity of 1700021P04Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that prevents the activation of ERK1/2. If the protein 1700021P04Rik is involved in cell signaling pathways that are negatively regulated by ERK, inhibition by PD98059 could result in enhanced activity of 1700021P04Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. The inhibition of p38 MAPK can lead to alterations in downstream signaling pathways. If 1700021P04Rik is involved in a pathway that is suppressed by p38 MAPK activity, SB203580 could indirectly activate 1700021P04Rik by lifting this suppression. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases PP1 and PP2A. Inhibition of these phosphatases could lead to increased phosphorylation levels of proteins. If 1700021P04Rik is activated by phosphorylation, okadaic acid could enhance its activity by preventing dephosphorylation. | ||||||